Health‐related quality of life · people with active UC
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review
Live birth · women undergoing assisted reproduction
It is very uncertain whether testosterone changes live birth ‐ Testosterone vs estradiol + OCP compared with other active interventions (very low certainty).
2 findings from 1 review
Miscarriage · women undergoing assisted reproduction
It is very uncertain whether testosterone changes miscarriage ‐ Testosterone vs estradiol compared with other active interventions (very low certainty).
2 findings from 1 review
Clinical pregnancy rate ‐ Testosterone vs estradiol · women undergoing assisted reproduction
It is very uncertain whether testosterone changes clinical pregnancy rate ‐ Testosterone vs estradiol compared with other active interventions (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · women undergoing assisted reproduction
It is very uncertain whether testosterone changes clinical pregnancy rate ‐ Testosterone vs estradiol + OCP compared with other active interventions (very low certainty).
1 finding from 1 review
Muscle pain at rest · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
It is very uncertain whether summary of findings: whole‐body cryotherapy (WBC) changes muscle soreness: pain at rest (VAS) compared with control (no WBC or passive rest) (very low certainty).
4 findings from 1 review
no estimate extracted
2 studies · 20 participants
Very low
no estimate extracted
3 studies · 38 participants
Very low
no estimate extracted
3 studies · 38 participants
Very low
Show 1 more finding
Tiredness · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
General well‐being · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Adverse events · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Index case management (6 to 12 weeks of · Sexually active people
Home‐based showed no clear difference in index case management (6 to 12 weeks of compared with clinic‐based specimen collection (moderate certainty).
1 finding from 1 review
Proportion of individuals tested (12 days to 8 weeks of · Sexually active people
1 finding from 1 review
Positive test prevalence · Sexually active people
Home‐based probably leads to lower positive test prevalence compared with clinic‐based specimen collection (moderate certainty).
1 finding from 1 review
Adverse effects of testingc · Sexually active people
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review